CAJ | 학술논문

目的：观察孟鲁司特钠对儿童咳嗽变异性哮喘(CVA)患者血清白介素-13(IL-13)、IgE、及全血嗜酸性粒细胞计数( EOS)水平的影响。方法100例CVA患儿,分为对照组和观察组各50例。对照组采用常规基础治疗,观察组在对照组常规基础治疗上加服孟鲁司特钠,药物干预共进行8周,观察治疗前后血清IL-13、IgE及外周血EOS表达水平变化及评价临床治疗疗效。结果治疗前两组患者IL-13、IgE、EOS比较,差异无统计学意义(P>0．05)。治疗8周后,观察组IL-13、IgE、EOS比对照组明显下降(P<0．05)；观察组总有效率为70.0%,对照组总有效率为36.0%,对照组总有效率明显高于对照组(χ2=11．602,P<0．05)。结论孟鲁司特钠治疗儿童CVA疗效显著、不良反应较少,明显改善哮喘、咳嗽等临床症状。
목적：관찰맹로사특납대인동해수변이성효천(CVA)환자혈청백개소-13(IL-13)、IgE、급전혈기산성립세포계수( EOS)수평적영향。방법100례CVA환인,분위대조조화관찰조각50례。대조조채용상규기출치료,관찰조재대조조상규기출치료상가복맹로사특납,약물간예공진행8주,관찰치료전후혈청IL-13、IgE급외주혈EOS표체수평변화급평개림상치료료효。결과치료전량조환자IL-13、IgE、EOS비교,차이무통계학의의(P>0．05)。치료8주후,관찰조IL-13、IgE、EOS비대조조명현하강(P<0．05)；관찰조총유효솔위70.0%,대조조총유효솔위36.0%,대조조총유효솔명현고우대조조(χ2=11．602,P<0．05)。결론맹로사특납치료인동CVA료효현저、불량반응교소,명현개선효천、해수등림상증상。
Objective To observe the effect of montelukast on the change of serum IL-13, IgE and blood eo-sinophil count in children with cough variant asthma. Methods 100 children with CVA were randomly divided into the control group (50 cases), which were given conventional therapy, and the study group (50 cases), which were given montelukast on the basis of the control group. The clinical efficacy and the changes of serum IL-13, IgE and blood eosinophil count were observed and compared. Results There was no significant difference in IL-13, IgE and EOS between the two groups before treatment (P>0. 05). The expression of IL-13, IgE and EOS decreased more significantly in the study group than in the control group 8 weeks after the treatment (P<0. 05). The clinical efficacy in the study group were better than that in the control group (χ2 =5. 955, P<0. 05). Conclusion Montelukast could significantly improve the clinical symptoms such as asthma and cough, with less adverse reactions in the treat-ment of children with CVA.